Decision and Details
General Meeting of the Central Social Insurance Medical CouncilReimbursement listing of リハート® (determination of the reimbursement price)
Because the General Meeting of the Central Social Insurance Medical Council approved the reimbursement listing and determined the reimbursement price.
The impact on consolidated results for the fiscal year ending March 2027 is currently being reviewed and will be disclosed promptly after the review is completed.
| Item | Details |
|---|---|
| Matter Covered | Reimbursement listing of リハート® (determination of the reimbursement price) |
| Decision-Making Body | General Meeting of the Central Social Insurance Medical Council |
| Decision Date | 22 July 2026 |
| Implementation Date | Scheduled for 1 September 2026 (reimbursement listing and Official Gazette notification date). Sales are scheduled to begin after reimbursement listing. |
| Amount | Reimbursement price: ¥53,200,000 |
| Quantity / scale | Marketability premium (I): 10%; add-on coefficient: 1.0 |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 is currently being reviewed and will be disclosed promptly after the review is completed. |
| Reason | Because the General Meeting of the Central Social Insurance Medical Council approved the reimbursement listing and determined the reimbursement price. |
| Related previous disclosures | Disclosure dated 6 March 2026 stating that conditional and time-limited marketing approval had been obtained (title: Not disclosed) |
| Future plans | Reimbursement listing is scheduled for 1 September 2026. Sales of リハート® will begin after reimbursement listing. Efforts toward overseas expansion will also continue. |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The General Meeting of the Central Social Insurance Medical Council approved the reimbursement listing of リハート® and determined its reimbursement price. The impact on consolidated results for the fiscal year ending March 2027 is currently being reviewed.